首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >Lentivector Integration Sites in Ependymal Cells From a Model of Metachromatic Leukodystrophy: Non-B DNA as a New Factor Influencing Integration
【2h】

Lentivector Integration Sites in Ependymal Cells From a Model of Metachromatic Leukodystrophy: Non-B DNA as a New Factor Influencing Integration

机译:从异质性白细胞营养不良模型的室管膜细胞中的慢病毒整合位点:非B DNA作为影响整合的新因素。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The blood–brain barrier controls the passage of molecules from the blood into the central nervous system (CNS) and is a major challenge for treatment of neurological diseases. Metachromatic leukodystrophy is a neurodegenerative lysosomal storage disease caused by loss of arylsulfatase A (ARSA) activity. Gene therapy via intraventricular injection of a lentiviral vector is a potential approach to rapidly and permanently deliver therapeutic levels of ARSA to the CNS. We present the distribution of integration sites of a lentiviral vector encoding human ARSA (LV-ARSA) in murine brain choroid plexus and ependymal cells, administered via a single intracranial injection into the CNS. LV-ARSA did not exhibit a strong preference for integration in or near actively transcribed genes, but exhibited a strong preference for integration in or near satellite DNA. We identified several genomic hotspots for LV-ARSA integration and identified a consensus target site sequence characterized by two G-quadruplex-forming motifs flanking the integration site. In addition, our analysis identified several other non-B DNA motifs as new factors that potentially influence lentivirus integration, including human immunodeficiency virus type-1 in human cells. Together, our data demonstrate a clinically favorable integration site profile in the murine brain and identify non-B DNA as a potential new host factor that influences lentiviral integration in murine and human cells.
机译:血脑屏障控制分子从血液进入中枢神经系统(CNS)的通道,是治疗神经系统疾病的主要挑战。变色性白细胞营养不良是由芳基硫酸酯酶A(ARSA)活性降低引起的神经退行性溶酶体贮积病。通过脑室内注射慢病毒载体进行基因治疗是将治疗水平的ARSA快速持久地传递给CNS的潜在方法。我们提出了在鼠脑脉络丛和室管膜细胞中编码人ARSA(LV-ARSA)的慢病毒载体的整合位点的分布,通过一次颅内注射到CNS中进行管理。 LV-ARSA在整合到主动转录的基因中或附近并没有表现出强烈的偏好,但是对于在卫星DNA内或附近的整合中表现出强烈的偏好。我们确定了LV-ARSA整合的几个基因组热点,并确定了以两个G-四链体形成基序为侧翼的整合目标的共有靶位点序列。此外,我们的分析还发现了其他几种非B DNA基序,它们是可能影响慢病毒整合的新因素,包括人类细胞中的人类免疫缺陷病毒1型。总之,我们的数据证明了鼠脑中临床上有利的整合位点,并确定了非B DNA作为潜在的新型宿主因子,可影响鼠和人细胞中的慢病毒整合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号